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Abstract 
Objective: First-degree atrioventricular block is frequently encountered in clinical practice 
and is generally considered a benign process.  However, there is emerging evidence that 
prolonged PR interval may be associated with adverse outcomes. This study aims to 
determine if prolonged PR interval is associated with adverse cardiovascular outcomes and 
mortality. 
Methods:  We searched MEDLINE and EMBASE for studies that evaluated clinical 
outcomes associated with prolonged and normal PR intervals.  Relevant studies were pooled 
using random effects meta-analysis for risk of mortality, cardiovascular mortality, heart 
failure, coronary heart disease, atrial fibrillation and stroke or transient ischemic attack.  
Sensitivity analyses were performed considering the population type and use of adjustments.   
Results: Our search yielded 14 studies that were undertaken between 1972 and 2011 with 
400,750 participants.  Among the studies that adjusted for potential confounders, the pooled 
results suggest an increased risk of mortality with prolonged PR interval RR 1.24 95%CI 
1.02-1.51, 5 studies.   Prolonged PR interval was associated with significant risk of heart 
failure or left ventricular dysfunction (RR 1.39 95%CI 1.18-1.65, 3 studies) and atrial 
fibrillation (RR 1.45 95%CI 1.23-1.71, 8 studies) but not cardiovascular mortality, coronary 
heart disease or myocardial infarction or stroke or TIA.  Similar observations were recorded 
when limited to studies of first-degree heart block.   
Conclusions:  Data from observational studies suggests a possible association between 
prolonged PR interval and significant increases in atrial fibrillation, heart failure and 
mortality.  Future prospective studies are needed to confirm the relationships reported, 
consider possible mechanisms and define the optimal monitoring strategy for such patients. 
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Key Questions: 
What is already known about this subject? 
• First-degree atrioventricular block, defined as PR interval greater than 200 ms, is 
frequently encountered in clinical practice.  
• In patients who are incidentally found to have first-degree heart block, current expert 
advice suggests that this poses little risk and is not associated with significant 
symptoms and no specific treatment is required. 
What does this study add? 
• Our review of 14 studies with over 400,000 participants suggests that prolonged PR 
interval was associated with increased risk of mortality, heart failure and atrial 
fibrillation.   
• Similar significant increases in mortality, heart failure and atrial fibrillation were 
observed when limited to studies of first-degree heart block.   
How might this impact on clinical practice? 
• Physicians should not automatically dismiss first degree heart block as a benign 
condition.   
• Contrary to current expert advice, our results suggest that closer monitoring may be 
warranted for future events, although effective risk reduction strategies still need to be 
developed.  
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Introduction 
 First-degree atrioventricular block (1°HB), defined as PR interval greater than 200 
ms, is frequently encountered in clinical practice and considered a benign process.[1,2]   The 
PR interval reflects the propagation of electrical impulses from the onset of atrial 
depolarization to the beginning of ventricular depolarization.  Although the prevalence of PR 
prolongation is relatively rare amongst the younger population (1% among those age <60 
years) it becomes much more common after the age of ≥60 years, with prevalence rising to 
6%.[3]  Whilst it has been suggested that enhanced vagal tone underlies the etiology of 1°HB 
in young people, organic heart disease is more prevalent in older subjects and may be linked 
to myocardial conduction system fibrosis and conduction abnormalities in these groups of 
patients.[4]  In patients who are incidentally found to have 1°HB, current expert advice 
suggests that 1°HB poses little risk, is not associated with significant symptoms and no 
specific treatment is required.[5-7] 
 The ACC/AHA/HRS 2008 guidelines suggest that permanent pacemaker is not 
indicated for asymptomatic 1°HB except for neuromuscular disease such as myotonic 
dystrophy[8] whilst the European Society of Cardiology recommends with class IIa and level 
C evidence that permanent pacemaker should be considered for patients with persistent 
symptoms similar to those of pacemaker syndrome and attributable to 1°HB (PR >0.3s).[9]  
 However, the current conservative approach to 1°HB may have been based on older 
studies with major methodological limitations.[10,11]  Judgments regarding the benign nature 
of 1°HB and prolonged PR interval may be erroneous because of small sample sizes, 
inadequate follow up to capture sufficient events, confounding, lack of adjustment for 
baseline characteristics or poor outcome ascertainment.  Several more recent studies have 
drawn association between prolonged PR interval and cardiovascular outcomes but there are 
clearly conflicting viewpoints in the existing literature.[12-17]  The only previous systematic 
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review evaluated the risk of atrial fibrillation with prolonged PR interval but this review did 
not look at other outcomes such as mortality and cardiovascular diseases.[18]  As there are 
several recent publications that have studied the association between prolonged PR interval / 
1°HB, we have re-assessed the relationship between prolonged PR interval / 1°HB and CV 
outcomes. We conduct a systematic review and meta-analysis to evaluate the association 
between prolonged PR interval or 1°HB and mortality, atrial fibrillation, heart failure, 
coronary heart disease and stroke. 
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Methods 
Eligibility criteria 
We selected studies that evaluated adverse outcomes in patients with and without 
1°HB or prolonged PR interval on electrocardiogram.  The adverse outcomes of interest were 
mortality, cardiovascular mortality, heart failure or left ventricular dysfunction, coronary 
heart disease or myocardial infarction, atrial fibrillation, stroke or transient ischemic attack, 
progression of heart block or need for pacemaker insertion.  While 1°HB is clearly defined as 
≥ 200 ms, we chose to also include studies that focused on “prolonged PR interval”, in which 
this was variably defined by individual authors as anywhere between >196ms to >220ms. 
Included studies had to have two groups (one with longer PR interval), which would allow 
risk estimates to be calculated.  There was no restriction based on study design, cohort type or 
language of study report.  However, we excluded studies of patients with specific cardiac 
pathologies that were uncommon (such as aortic stenosis, sinus nodal dysfunction, heart 
failure) or had received intervention (angiography or cardiac resynchronization therapy) from 
the main analysis. 
Search strategy 
 We searched MEDLINE and EMBASE using OVID SP with no date or language 
restriction in May 2015.  The exact search terms were: (first degree atrioventricular heart 
block or prolonged PR interval or PR prolongation or first-degree atrioventricular block) 
AND (atrial fibrillation or myocardial infarction or acute coronary syndrome or ischemic 
heart disease or ischemic heart disease or coronary heart disease or coronary artery disease or 
stroke or cerebrovascular disease or cerebrovascular accident or heart failure or cardiac 
failure or mortality or death).  We checked the bibliography of relevant studies and reviews 
for additional studies that met the inclusion criteria. 
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Study selection and data extraction 
 Two reviewers (CSK, MR) screened all titles and abstracts retrieved from the search 
for studies that met the inclusion criteria.  The full manuscript of studies that potentially met 
the inclusion criteria were reviewed and the final decision to include or exclude studies were 
made with two other reviewers (YKL, MAM).  Independent double extractions were 
performed by two reviewers (CSK, MR) and data was collected on study design, year, 
country, number of participants, mean age, % male, participant inclusion criteria, definition 
of prolonged PR interval, outcomes evaluated, timing of assessment and results.  
Risk of bias assessment 
Quality assessment of the studies was conducted with consideration of ascertainment 
of PR prolongation, outcome ascertainment, loss to follow up and use of adjustments for 
medication, cardiovascular disease and other adjustments.  
Data analysis 
 We used RevMan 5.3.5 (Nordic Cochrane Centre) to conduct random effects meta-
analysis using the inverse variance method for pooling log risk ratios (RR).  We used random 
effects because the studies were conducted in a wide range of settings in different 
populations, hence the need to take heterogeneity into account for the pooled effect estimate.  
Where possible, we chose to pool adjusted risk estimates from primary studies and when this 
data was not available raw data was used to calculate unadjusted risk estimates.  The primary 
outcome was all-cause mortality and analysis was performed considering adjusted and 
unadjusted group separately.  Subgroup analysis was performed considering whether the 
population evaluated was a general population or subjects with cardiovascular disease.  We 
also performed sensitivity analysis by including only studies which evaluated 1°HB (>200ms 
or ≥200 ms) excluding studies which did not adjust for a) medications and b) cardiovascular 
disease.
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Results 
Description of studies included in analysis 
 The progress of study selection is shown in Supplementary Figure 1. Out of the 879 
studies retrieved from the search, 26 studies were relevant but 12 studies were excluded from 
the analysis (Supplementary Table 1).  A total of 14 studies [4,10-17,20-24] were included: 
12 general population studies, 1 cohort with coronary heart disease[20] and 1 cohort with 
hypertension.[16] 
 Table 1 shows the baseline characteristics of the participants.  There were a total of 
400,750 participants amongst the 14 studies (11 prospective cohort studies [4,10-13,17,20-
24], 3 retrospective cohort studies[14-16]).  The mean age from the 10 studies was 56 years 
and the percentage of participants that were male ranged from 18% to 100%..  The studies 
were undertaken between 1972 and 2011 and were undertaken in Finland, USA, Norway, 
Japan, Korea, Australia and Denmark.  Prevalence of prolonged PR interval ranged from 2% 
to 14% across 7 studies and the mean prevalence was 7%.  
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Table 1: Study design and participant characteristics 
Study ID Study design; year; country No. of 
participants 
Mean age, 
median 
age or age 
range 
% Male Participant inclusion criteria 
Aro 2014 Prospective cohort study; 1966 
to 2007; Finland. 
10,785 Mean 44 
years. 
52% Participants were ‘apparently healthy’ community 
population, aged 30-59 years between 1966 and 1972 
in the Finnish Social Insurance Institution's Coronary 
Heart Disease Study. 
Cheng 2009 Prospective cohort study; 1968 
to 2007; USA. 
7,575 Mean 47 
years. 
46% Participants were community-based individuals from 
the Framingham Heart Study. 
Crisel 2011 Prospective cohort study; 
enrolment 2000 to 2002; USA. 
938 Mean 66 
years. 
82% Participants had stable coronary artery disease in the 
Heart and Soul Study. 
Erikssen 
1984 
Prospective cohort study; 
enrolment 1972-1975; 
Norway. 
1,635  40-59 
years at 
baseline. 
100% Participants were ‘apparently healthy’ men aged 40-59 
years free of coronary heart disease. 
Hisamatsu 
2015 
Prospective cohort study; 1980 
to 2009; Japan. 
9,051 Mean 50 
years. 
44% Participants were community dwellers, aged 30-95 
years from 300 randomly selected areas throughout 
Japan. 
Knuiman 
2014 
Prospective cohort study; 1994 
to 2010; Australia. 
4,267 Mean 52 
years. 
44% Participants were community-based adults, age 25-84 
years in the Busselton Health Study. 
Kobayashi 
2014 
Prospective cohort study; 
baseline survey 1989 to 1994; 
Japan. 
5,425 30-83 
years. 
47%. Participants were Japanese urban adults age 30-83 
years without prior cardiovascular disease who 
attended a routine examination. 
Magnani 
2013 
Prospective cohort study; 1997 
to 2011; USA. 
2,722 Mean 74 
years. 
48%. Participants were a random sampling of community-
dwelling older patients (age 70-79 years) free of 
disability or functional limitation from the Health, 
Aging and Body Composition Study. 
Nielsen 2013 Prospective cohort study; 2001 
to 2010; Denmark. 
288,181 Median 54 
years. 
45%. Participants were from primary care who had ≥1 ECG 
recorded at the Copenhagen General Practitioners' 
Laboratory. 
11 
 
Perez 2009 Retrospective cohort study; 
Mar 1987 to Jul 2000; USA. 
42,751 Mean 56 
years. 
90%. Participants had initial ECG between Mar 1987 and Jul 
2000. Indications for ECG and background disease – 
not known, but patients with known AF were excluded 
from study. 
Rajala 1985 Prospective cohort study; Jan 
1977 to Dec 1982; Finland. 
674 Age >85 
years. 
18%. Participants were 85 years or older community-based 
sample living in the city of Tampere in 1977. 
Soliman 
2009 
Retrospective cohort study; 
1987 to 1998; USA. 
15,429 Mean 54.2 
years. 
45%. Participants were from 4 US communities aged 45 to 
64 years in the Atherosclerosis Risk in Communities 
study. 
Soliman 
2014 
Prospective cohort study; 1988 
to Dec 2006; USA. 
7,501 Mean 59.3 
years. 
47%. Participants were civilian noninstitutionalized US 
population in the NHANES study. 
Uhm 2013 Retrospective cohort study; 
Unclear; Korea.  
3,816 Mean 61.0 
years. 
47.2%. Participants were age >18 years with hypertension and 
sinus rhythm on first ECG. 
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Risk of bias in studies 
 The evaluation of the quality of studies is shown in Supplementary Table 2.  All 
studies used ECG to ascertain PR prolongation but only eight studies reported the leads used 
to measure PR interval.  A variety of methods were used to ascertain outcomes including data 
from registries, telephone contact and medical records.  Seven studies reported some degree 
of loss to follow up which ranged from 1% to 9%.  Aside from two studies, all the studies 
used multivariate analysis to adjust for potential confounders (9 adjusted for medications, 7 
adjusted for cardiovascular disease and 8 adjusted for heart rate).  Two studies with 
unadjusted data were considered to be at high risk of bias.[10,11] 
 
Description of included studies 
Table 2 shows the description of reference group, outcomes evaluated, timing of 
assessment and results.  The definition of PR prolongation varied across the studies from 
>196 ms to >220 ms and follow up for outcomes amongst studies was between 5 to 24 years.  
Seven studies used the 200 ms as the cut off and were included in the 1°HB analysis. 
 
Risk of adverse outcomes with prolonged PR interval 
The risk of mortality with prolonged PR interval is shown in Figure 1a).  There were a 
total of seven studies in the analysis and five of which adjusted for potential confounders.  
The pooled estimate of adjusted studies (based on a total of 14,454 deaths/37,634 
participants) suggests a significant increase in mortality with prolonged PR interval (RR 1.24 
95% CI 1.02-1.51). The crude event rate for the two unadjusted studies was 547 deaths/2,331 
participants (38%).  The pooled estimate from unadjusted analyses (that are at high risk of 
bias) showed that prolonged PR interval was associated with reduced overall mortality (RR 
0.72 95% CI 0.55-0.99). 
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 The risk of other adverse outcomes with prolonged PR interval is shown in Figure 
1b).  Prolonged PR interval was associated with significant risk of heart failure or left 
ventricular dysfunction (RR 1.39 95%CI 1.18-1.65, 3 studies, event rate 2,389/17,323, 14%) 
and atrial fibrillation (RR 1.45 95%CI 1.23-1.71, 8 studies, event rate 15,616/375,526, 4%) 
but not cardiovascular mortality, coronary heart disease or myocardial infarction or stroke or 
TIA. 
 Additional analysis was performed considering all studies including patients with 
previous coronary heart disease and hypertension and adjustments for medication and 
cardiovascular disease (Table 3).  We observed similar significant increases in adjusted 
mortality, heart failure or LV dysfunction and atrial fibrillation in these additional analyses. 
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Table 3: Summary of meta-analysis results 
A) General population studies 
Adverse outcome General population studies 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
Unadjusted only 
 
5 
2 
 
14,454/37,634 
15,001/39,965 
 
1.24 (1.02-1.51) 
0.73 (0.55-0.99) 
Cardiovascular 
mortality 
3 3,086/21,471 0.93  (0.74-1.17) 
Heart failure or LV 
dysfunction 
3 2,389/17,323 1.39 (1.18-1.65) 
CHD or MI 4 4,006/26,896 1.08 (0.85-1.36) 
Atrial fibrillation 8 15,616/37,526 1.45 (1.23-1.71) 
Stroke or TIA 4  1.13 (0.82-1.56) 
B) All studies (including studies of patients with CAD) 
Adverse outcome All studies (including studies of patients with CAD) 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
Unadjusted only 
 
7 
2 
 
14,739/38,572 
547/2,331 
 
1.23 (1.01-1.49) 
0.73 (0.55-0.99) 
Cardiovascular 
mortality 
4 3,153/22,409 1.14 (0.73-1.76) 
Heart failure or LV 
dysfunction 
4 2,512/18,261 1.51 (1.22-1.88) 
CHD or MI 4 4,006/26,896 1.08 (0.85-1.36) 
Atrial fibrillation 8 15,616/375,526 1.45 (1.23-1.71) 
Stroke or TIA 4 3,258/40,690 1.13 (0.82-1.56) 
C) Only inclusion of studies that adjusted for medications 
Adverse outcome Only inclusion of studies that adjusted for medications 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
 
7 
 
14,739/48,209 
 
1.23 (1.01-1.49) 
Cardiovascular 
mortality 
3 3,116/20,774 1.19 (0.75-1.88) 
Heart failure or LV 
dysfunction 
4 2,512/18,261 1.51 (1.22-1.88) 
CHD or MI 1 3,539/10,785 0.97 (0.77-1.22) 
Atrial fibrillation 6 14,449/317,346 1.50 (1.15-1.96) 
Stroke or TIA 2 2,418/19,836 1.00 (0.59-1.70) 
D) Only inclusion of studies that adjusted for CVD 
Adverse outcome Only inclusion of studies that adjusted for CVD 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
 
6 
 
11,470/39,158 
 
1.26 (1.02-1.56) 
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Cardiovascular 
mortality 
2 2,015/11,723 1.42 (0.59-3.46) 
Heart failure or LV 
dysfunction 
4 2,512/18,261 1.51 (1.22-1.88) 
CHD or MI 1 3,539/10,785 0.97 (0.77-1.22) 
Atrial fibrillation 5 14,106/313,079 1.53 (1.14-2.04) 
Stroke or TIA 1 1,927/10,785 1.23 (0.93-1.63) 
CAD=coronary artery disease, CVD=cardiovascular disease, CHD=coronary heart disease, 
MI=myocardial infarction, TIA=transient ischemic attack 
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 In addition, Cheng et al was the only study to report two important outcomes 
associated with 1°HB which were need for pacemaker insertion and progression of heart 
block. 
 The results for adverse outcomes with prolonged PR interval using the cutoffs for 
1°HB are shown in Figure 2.  Similar to prolonged PR interval there were significant 
increases in mortality (RR 1.31 95% CI 1.18-1.46), heart failure (RR 1.39 95% CI 1.18-1.65) 
and atrial fibrillation (RR 1.47 (1.18-1.83) but not cardiovascular mortality, coronary heart 
disease or stroke.
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Discussion 
 Our results suggest that prolonged PR interval and 1°HB are not benign conditions 
and are associated with increased mortality, heart failure and atrial fibrillation.  Physicians 
should not therefore consider 1°HB as a benign condition.  Contrary to current expert advice, 
our results suggest that closer monitoring may be warranted for future events, although 
effective risk reduction strategies still need to be developed.  
 The mechanism that underlies the association between 1°HB and adverse 
cardiovascular outcomes and mortality is unclear.  Cheng et al suggests that chronic PR 
prolongation could be a precursor to more severe degrees of conduction block.[12]  This is 
supported by their findings that there was a significant increase in need for pacemaker and 
progression of heart block with 1°HB.[12]   Further evidence supporting the progression of 
heart block is provided by a study of 446 participants with acute myocardial infarction which 
found that one third of those who developed first degree heart block progressed to third 
degree heart block.[25]  Progression of heart block may relate to underlying causes of 
atrioventricular block and progression of these pathologies which include primary or 
idiopathic (generally considered as fibrosis in origin), and secondary to conditions such as 
coronary heart disease, calcification, inflammation, infiltrative diseases and neuromuscular 
disorders.[26]  Myocardial fibrosis is known to slow conduction and increase vulnerability to 
arrhythmia.[27]  Fibrosis of the conduction tissue is a dynamic process which can accumulate 
with repeated insults secondary to these pathological processes.  These accumulated changes 
over time may explain the initial manifestation of first degree heart and progression to higher 
degree of heart block and mortality. 
 Cheng et al also suggest that prolongation of PR interval may be a marker of other 
cardiovascular changes associated with worse prognosis such as advanced physiological 
age.[12] Electrophysiological studies which have demonstrated that atrial conduction velocity 
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in both atria declines and the atria becomes more refractory with increasing age; this may 
explain age related increase in prevalence of atrial fibrillation.[28,29]  Aging can also 
manifest as calcification or fibrosis of the cardiac skeleton.[12]  In addition, age is known to 
be associated with increased risk of mortality and cardiovascular disease such as ischemic 
heart disease and heart failure.  We observed a greater mean age in patients in the prolonged 
PR interval group compared to normal PR interval group in several studies.[4,12,13,17,20]  
However, the majority of the included studies adjusted for age which suggests that the 
increased risk of cardiovascular events with 1°HB cannot be explained by ageing alone.    
 Crisel et al suggest that 1°HB may be a marker of diffuse ischemic heart disease.[20]  
However, our findings do not support this as prolonged PR interval does not increase 
coronary heart disease, stroke and cardiovascular mortality which are related to 
atherosclerosis and vascular pathology.  Magnani et al suggest that prolongation of PR has 
been associated with obesity, waist circumference and components of metabolic syndrome 
which are also associated with incident heart failure.[23]  They also suggest that hypertension 
may be a confounder that causes heart failure with both preserved and compromised systolic 
function and cause elevated intra-cardiac pressures and secondary altered atrial electrical 
function.[23]  In addition, prolonged PR interval may unmask existing cardiac pathology 
such as heart failure.  
 Our results support the findings of existing studies.  Cheng et al conducted a meta-
analysis of six cohort studies and reported an increased risk of atrial fibrillation with 
1°HB.[18]  There are two additional studies in our review, Perez et al[14] and Uhm et al[16] 
and both of these studies suggest an increased risk of atrial fibrillation with 1°HB.  We build 
upon this review by including the other outcomes mortality, cardiovascular mortality, heart 
failure, coronary heart disease and stroke. 
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We identified three older studies suggesting no increase in mortality with AV block or 
first degree heart block but these studies did not provide specific statistical analyses and 
results that met our criteria for inclusion in the meta-analysis. The study by Kitchin et al, 
evaluated mortality rates of 487 random adults with and without AV block.[30]  Mortality 
was lower in the AV block group compared to control group (21% vs 24%) but the study did 
not report specifically on first degree heart block.  The study by Rose et al, evaluated 
coronary heart disease death at 5 years with different ECG abnormalities.[31]  However, 
confidence intervals for the adjusted rates were not reported.  The Copenhagen City Heart 
study of 19,662 adults stated that there was no difference between the normal ECG group and 
those with AV conduction defects but did not quantify outcome data.[32]  We believe that 
there is insufficient granularity in data from these older studies for us to make any robust 
interpretation on cardiovascular or mortality risk. Moreover, the population and management 
of cardiovascular disease has changed substantially since these older studies, so it is unclear 
if these results are generalizable to current practice. 
 The long follow up in many of these studies is an important consideration in the 
interpretation of the findings.  This may suggest that event rates may be very low so a long 
follow up time is need to capture enough events to show a difference.  Because 1°HB can be 
asymptomatic it is unclear exactly how long patients have had heart block for prior to 
inclusion in the study.  This represents a problem because all of the studies are observational 
in nature.  However, the long follow up time between heart block and adverse events may 
provide a window for which patients can be identified and management can be implemented 
to reduce risk of cardiovascular pathology.   
 While first degree heart block is generally considered to be PR interval greater than 
200 ms the upper limit of the "normal" PR interval is necessarily arbitrary.[3]  In the current 
study, prolonged PR interval ranged from 196 to 220 ms.   
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 An important question generated from these findings is the management strategy that 
should be undertaken if 1°HB is incidentally found.  Guidelines recommend against 
pacemaker insertion unless patients are symptomatic and according to ESC guidelines the PR 
interval is >300 ms.[7,9]  The options include following up these patients and if so how 
frequently (probably unrealistic to see them yearly, perhaps every 3 years or 5 years).  
Furthermore, it is unclear whether formal cardiovascular risk assessment should be 
undertaken as recommended for high risk groups at risk of future cardiovascular events such 
as those with established cardiovascular disease, diabetes mellitus and renal disease.[33] 
While we were able to show significant associations between prolonged PR interval 
and certain adverse outcomes (e.g. mortality, atrial fibrillation and heart failure) the pooled 
effect sizes are small and there are only a limited number of studies for each outcome.  
Consequently, the findings may be affected by the possibility of residual confounding.  
Therefore, findings of this current systematic review should be interpreted as evidence to 
raise the hypothesis that prolonged PR interval may be a risk factor for several adverse 
cardiac outcomes.  These results do support further studies to assess the association of 
prolonged PR interval and adverse cardiovascular outcome but at present we cannot 
definitely conclude that the association is causal.  
We observed differences in study results and this may be attributed to dissimilarity among the 
include studies in terms of geographic locations, baseline cardiovascular risk and underlying 
aetiology of prolonged PR interval.  Equally, the effects of potential confounding factors may 
vary across the studies because of these differences.  Collectively, these factors are likely 
contribute to clinical heterogeneity in effect sizes.  In addition, we note that the participants 
in the currently pooled studies are of different design with different inclusion criteria.  This 
form of methodological heterogeneity among the studies may account for different results in 
each study.  Therefore it is possible that for some populations, prolonged PR interval may be 
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a benign finding. Our study has a number of strengths and limitations.  We included over 
400,000 subjects from 12 studies. We were able to consider the effects of adjustments 
including the impact of adjustments for medications and cardiovascular disease.  
Furthermore, we evaluated a variety of clinically relevant cardiovascular outcomes.  All of 
the included studies are all observational in nature.  For some cardiovascular events follow 
up, the outcome ascertainment is less reliable but mortality events are easily ascertained.  
This is a problem for outcomes that may be asymptomatic such as atrial fibrillation especially 
in studies that use hospitalization data.  We also observed either a lack of description of the 
leads use for evaluation of PR interval or inconsistencies in choice of leads for evaluation for 
heart block among the included studies. We were also unable to determine if prolongation of 
PR interval was persistent among the studies.  Additional limitations include the lack of 
trending data with regards to the degree of PR-interval and risk of adverse outcomes.  
Furthermore, an important consideration is use of pharmacological agents which could 
impact PR prolongation.  We found that 8 studies adjusted for medications as potential 
confounders and 1 study excluded patients on nodal-blocking medications while 6 studies did 
not consider the effects of medications.  There are also limitations because end points have 
been defined and measured in different ways and at different time points amongst the studies. 
Conclusions 
In a relatively, unselected population of patients in this meta-analysis, PR interval 
prolongation might be associated with adverse cardiovascular events and mortality but further 
studies are needed.  Future studies should also focus on providing mechanistic insight and 
define the optimal monitoring strategy for such patients. 
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